Skip to main content
IMMUPHARMA PLC logo

IMMUPHARMA PLC — Investor Relations & Filings

Ticker · IMM ISIN · GB0033711010 LEI · 213800VZKGHXC7VUS895 IL Professional, scientific and technical activities
Open in API
Filings indexed 442 across all filing types
Latest filing 2025-02-13 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL IMM

About IMMUPHARMA PLC

https://www.immupharma.co.uk/

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The company's primary focus is on creating novel treatments for serious medical conditions with significant unmet needs. Its core activities involve advancing a pipeline of drug candidates through research and various stages of clinical development, leveraging its expertise in peptide technology.

Recent filings

Filing Released Lang Actions
£2.91m fundraising; related party transactions
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement (RNS Number: 9292W) detailing a significant financial transaction: an equity fundraise comprising an oversubscribed placing and a subscription with a major shareholder (Lanstead Capital Investors L.P.). It explicitly announces the raising of c.£2.91 million through the issue of new ordinary shares and details the terms of a related 'Sharing Agreement'. This content directly relates to fundraising, capital structure changes, and the issuance of new shares. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple Dividend Notice (DIV). Since it is a detailed announcement of a financing event, CAP is the most appropriate classification, rather than the general fallback (RNS). The document length (24,323 chars) suggests it is the primary filing, not just a brief announcement of a report (RPA).
2025-02-13 English
Response to Share Price Movement
Regulatory Filings Classification · 1% confidence The document is identified by the header 'RNS Number : 9943U' and concludes with standard RNS boilerplate text, indicating it is a regulatory announcement distributed via the London Stock Exchange's RNS service. The content is a brief statement titled 'Response to Share Price Movement,' where the company addresses recent stock volatility by referencing prior announcements and ongoing discussions, concluding that they are 'not aware of any further material commercial or operational reason' for the movement. This type of short, market-sensitive update that doesn't fit neatly into specific financial reporting categories (like ER, 10-K, or DIV) is best classified as a general Regulatory Filing or announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a standard RNS announcement that isn't a specific report type.
2025-01-28 English
Breakthrough Findings into Autoimmune Diseases
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 7285S' and is dated '09 January 2025'. It announces 'breakthrough findings' regarding a drug candidate (P140) for autoimmune diseases. The text explicitly states, 'This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation...' and concludes with boilerplate text from 'RNS, the news service of the London Stock Exchange.' This structure is characteristic of a regulatory news service announcement, which falls under the general category of Regulatory Filings (RNS) when the content is not a specific financial report (like 10-K, ER, or IR) or a specific corporate action (like DIV or CAP). Since it is an announcement of research findings and intellectual property strategy, RNS is the most appropriate general regulatory filing category.
2025-01-09 English
IMM at JP MORGAN CONFERENCE & BIOTECH SHOWCASE
Regulatory Filings Classification · 1% confidence The document is identified by the header 'RNS Number : 4505S' and contains an announcement about the company's CEO and COO attending industry conferences (JP Morgan Conference and Biotech Showcase) to discuss licensing agreements. This is a general corporate update regarding business development and investor engagement, not a formal financial report (like 10-K or IR), a specific regulatory filing (like DIRS or DIV), or a transcript. The footer explicitly mentions that 'Reach announcements' distribute 'marketing messages, corporate and product information' and that an RNS Regulatory announcement is required for AIM Rules compliance, suggesting this is a non-regulatory corporate news release distributed via the RNS system. Since it is a general corporate announcement that doesn't fit the highly specific categories like AGM-R, ER, or CT, the most appropriate fallback category is Regulatory Filings (RNS), which often captures these types of general news releases distributed through the RNS platform.
2025-01-08 English
Change of Auditor
Audit Report / Information Classification · 1% confidence The document is very short (3047 characters) and is clearly marked with an 'RNS Number' and boilerplate text from the London Stock Exchange's news service ('This information is provided by RNS...'). The core content announces a 'Change of Auditor' for Immupharma PLC, effective immediately, and mentions the future proposal for reappointment at the 2025 AGM. This type of immediate, non-financial, operational announcement that is distributed via the RNS system fits best under the general 'Regulatory Filings' category, as it is not a specific financial report (10-K, IR, ER) or a management change (MANG), but rather a required regulatory disclosure. Given the source (RNS) and the nature of the announcement (Change of Auditor), RNS is the most appropriate classification, as it serves as a general regulatory disclosure mechanism. FY 2024
2024-12-23 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains RNS Number information, indicating it is a regulatory filing related to share ownership changes. Section 2 marks 'An acquisition or disposal of voting rights' as the reason. Section 7 details the resulting shareholding percentage (6.90%) compared to the previous notification (9.99%). This type of filing, which reports changes in significant share ownership thresholds, directly corresponds to the Major Shareholding Notification category.
2024-12-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.